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AbstrAct
Objectives The International Classification of Diseases 
10th Revision (ICD-10) system used in the English hospital 
administrative database (Hospital Episode Statistics 
(HES)) does not contain a specific code for oesophageal 
high-grade dysplasia (HGD). The aim of this paper was to 
examine how patients with HGD were coded in HES and 
whether it was done consistently.
Setting National population-based cohort study of patients 
with newly diagnosed with HGD in England. The study 
used data collected prospectively as part of the National 
Oesophago-Gastric Cancer Audit (NOGCA). These records 
were linked to HES to investigate the pattern of ICD-10 codes 
recorded for these patients at the time of diagnosis.
Participants All patients with a new diagnosis of HGD 
between 1 April 2013 and 31 March 2014 in England, who 
had data submitted to the NOGCA.
Outcomes measured The main outcome assessed was 
the pattern of primary and secondary ICD-10 diagnostic 
codes recorded in the HES records at endoscopy at the 
time of diagnosis of HGD.
Results Among 452 patients with a new diagnosis of 
HGD between 1 April 2013 and 31 March 2014, Barrett’s 
oesophagus was the only condition coded in 200 
(44.2%) HES records. Records for 59 patients (13.1%) 
contained no oesophageal conditions. The remaining 
193 patients had various diagnostic codes recorded, 
93 included a diagnosis of Barrett’s oesophagus and 
57 included a diagnosis of oesophageal/gastric cardia 
cancer.
Conclusions HES is not suitable to support national 
studies looking at the management of HGD. This is one 
reason for the UK to adopt an extended ICD system (akin 
to ICD-10-CM).
IntroductIon
It is well recognised that Barrett’s oesophagus 
may progress to oesophageal adenocarcinoma 
through a dysplasia carcinoma sequence.1 
The risk of progression to adenocarcinoma 
depends on the presence and severity of 
dysplasia. In non-dysplastic Barrett’s, the risk 
is only 0.1% per year2 and the disease can be 
managed by surveillance alone. If high-grade 
dysplasia (HGD) is present, the risk of 
progression increases to 5.6% per year3 and 
active treatment is recommended.4
Since April 2012, patients with a new diag-
nosis of oesophageal HGD in England have 
been eligible for inclusion in the National 
Oesophago-Gastric Cancer Audit (NOGCA). 
Hospitals prospectively collect data on patient 
characteristics, the results of the diagnostic 
endoscopy, planned treatment modality and 
pathology of the tissue after endoscopic or 
surgical resection.
A challenge for the Audit has been to derive 
the number of HGD patients in England, 
and thereby monitor case ascertainment. 
For patients diagnosed with oesophageal 
cancer, it is possible to derive the number 
of cases using the Hospital Episode Statistics 
(HES) administrative database.5 HES uses the 
International Classification of Diseases 10th 
Revision (ICD-10) disease classification6 to 
capture clinical conditions, and this contains 
clear codes for cancer diagnoses. Unfortu-
nately, the standard ICD-10 system is not 
Coding of Barrett’s oesophagus with 
high-grade dysplasia in national 
administrative databases: a population-
based cohort study
Georgina Chadwick,1 Mira Varagunam,1 Christian Brand,1,2 Stuart A Riley,3 
Nick Maynard,4 Tom Crosby,5 Julie Michalowski,6 David A Cromwell1,2 
to cite: Chadwick G, 
Varagunam M, Brand C, et al. 
Coding of Barrett’s oesophagus 
with high-grade dysplasia 
in national administrative 
databases: a population-
based cohort study. BMJ Open 
2017;7:e014281. doi:10.1136/
bmjopen-2016-014281
 ► Prepublication history 
and additional materials are 
available. To view these files 
please visit the journal online 
(http:// dx. doi. org/ 10.1136/
bmjopen-2016-014281).
Received 14 September 2016
Revised 20 April 2017
Accepted 11 May 2017
1Clinical Effectiveness Unit, The 
Royal College of Surgeons of 
England, London, UK
2Department of Health Services 
Research and Policy, London 




General Hospital, Sheffield, UK
4Oxford Health NHS Trust, 
Department of Oesophago-
Gastric Surgery, Oxford, UK
5Department of Radiotherapy, 
Velindre Cancer Centre, Cardiff, 
UK
6Health and Social Care 
Information Centre, Leeds, UK
Correspondence to
Professor David A Cromwell;  
 dcromwell@ rcseng. ac. uk
Research
Strengths and limitations of this study
 ► Study used data collected prospectively for all 
patients diagnosed with high-grade dysplasia (HGD) 
of the oesophagus in England linked with Hospital 
Episode Statistics (HES), and therefore provides 
representative results about the current coding of 
HGD in HES.
 ► Case ascertainment of HGD cases by the audit 
is uncertain, but there is no reason to believe 
that the cases submitted to the audit would differ 
systematically in how they were recorded in HES 
compared with those not submitted.
 ► The study used data submitted by hospitals to a 
central database and data recorded in HES. It was 
not possible to validate data from either source 
against medical records.
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specific for different types of Barrett’s oesophagus, and it 
is unclear how hospitals are using ICD-10 codes to record 
a diagnosis of HGD. The aim of this study is to explore 
which diagnostic codes are currently being used to record 
oesophageal HGD in HES and to assess the consistency of 
this coding.
Methods
This study used a linked dataset that combined informa-
tion from the records of patients in the NOGCA and HES. 
Patients were eligible for the study if they were diagnosed 
with oesophageal HGD in England between 1 April 2013 
and 31 March 2014, and we were able to link their record 
in the NOGCA with records contained in an extract of 
HES that covered all hospital admissions between April 
2012 and March 2015. Patient records were linked by 
matching the patient’s National Health Service number 
(a unique identifier for each UK resident) held in each 
dataset.
Each HES record describes the episode of care during 
which a patient is under the care of a hospital consultant. 
Patient conditions are described using a primary diag-
nosis and up to 19 secondary diagnoses, and a record 
can hold up to 24 procedures (coded using the Office 
of Population, Censuses and Surveys (OPCS)-4 Classifica-
tion of Interventions and Procedures7).
For each patient in NOGCA, we identified all HES 
records relating to that patient. Using the date of diag-
nosis of HGD in the NOGCA record, we identified the 
HES episode with a start date closest to this date, and 
selected this record for analysis. Using predefined OPCS 
codes (see online supplementary appendix 1), any endo-
scopic procedures the patient had during this episode 
were identified. Patients were dropped from analysis if 
they did not have any endoscopic procedures recorded 
during this episode. Furthermore, a few patients had 
more than one episode with the same start date; in these 
cases, the record with most information relating to endo-
scopic procedures performed was selected.
Using this cohort of HGD patients, we then examined 
the pattern of primary and secondary ICD-10 diagnostic 
codes in the HES records, describing the common combi-
nations of codes in terms of whether Barrett’s oesophagus 
or other related pathology was recorded. The analysis was 
performed using STATA V.14 (Statacorp).
The study was exempt from the UK National Research 
Ethics Committee approval as it involved the secondary 
analysis of existing data for service evaluation. Section 
251 approval was obtained for the collection of the 
personal health data from the Ethics and Confidentiality 
Committee.
results
The linked NOGCA-HES dataset contained 474 patients 
diagnosed with oesophageal HGD between 1 April 2013 
and 31 March 2014. Among these, 22 patients did not 
have an endoscopy procedure recorded in the HES 
episode nearest the date of HGD diagnosis and these 
patients were excluded, leaving 452 patients for analysis.
The frequent combinations of diagnostic codes entered 
into the HES records are summarised in table 1. There 
were 293 (64.8%) patients who had Barrett’s oesophagus 
recorded in any diagnosis field, and this was the primary 
diagnosis recorded for 225 patients. Unexpectedly, anal-
ysis found that 59 (13.1%) patients had no record of any 
oesophageal pathology recorded in HES.
Table 1 Diagnostic fields recorded in HES records among patients diagnosed with high-grade dysplasia of the oesophagus in 
the national oesophagogastric cancer audit






code for Barrett’s 
oesophagus
  K227 Barrett’s oesophagus with no additional 
codes
200 44 200 NA
  C15x Malignant neoplasm of oesophagus 57 13 24 33
  C160 Malignant neoplasm of gastric cardia
  D001 Carcinoma in situ oesophagus 13 3 6 7
  D130 Benign neoplasm of oesophagus 16 4 6 10
  D377 Neoplasm of uncertain/unknown behaviour 
in oral cavity and digestive organs
  K221 Oesophageal ulcer 29 6 14 15
  K20x, K21x Other benign oesophageal pathology not 
otherwise accounted for
78 17 43 35
  K22x*, K23x
No oesophageal pathology recorded 59 13 NA 59
Overall 452 293 159
*Excluding K227 (Barrett’s oesophagus) and K221 (oesophageal ulcer).
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For 200 (68.3%) of the 293 patients with a diagnosis 
of Barrett’s, this was the only diagnosis recorded, high-
lighting the fact that, in many cases, no additional code 
relating to oesophageal pathology was recorded to indi-
cate evidence of dysplasia. For the 93 patients who had 
another diagnostic code recorded in addition to Barrett’s, 
the most frequent codes were for benign oesophageal 
pathology (43) and upper gastrointestinal cancer/cancer 
in situ (36).
dIscussIon
Barrett’s oesophagus is a known premalignant condition 
for oesophageal cancer,1 and the incidence of oesopha-
geal cancer and Barrett’s oesophagus has risen steeply 
over the recent years.8 While the management of this 
group of patients can be examined using national regis-
tries or clinical audits, a weakness of this approach is 
having confidence all eligible cases are being captured.
In other situations, a common approach to determine 
the case ascertainment of a registry is to compare it to 
the data in a national administrative hospital dataset. In 
England, this study demonstrates that the HES database 
cannot fulfil this function in relation to patients with 
oesophageal HGD because the coding in HES records 
is variable. The study found that a third of HGD patients 
reported to the NOGCA had no HES record of a diag-
nosis of Barrett’s oesophagus at the time of diagnosis 
of HGD. Furthermore, where a diagnosis of Barrett’s 
oesophagus was recorded, HES cannot be used to iden-
tify those patients who had the disease complicated by the 
presence of HGD. It was unexpected to find 57 patients 
with a diagnosis of cancer recorded in HES. This suggests 
that some patients either had a HGD record incorrectly 
submitted to the NOGCA (instead of a cancer record 
if both HGD and cancer were present on the initial 
biopsy or the cancer was incorrectly coded in HES). We 
explored this issue by reviewing the pathology records 
of patients with HGD who had an endoscopic mucosal 
resection (EMR). Among the 25 patients with a diagnosis 
of cancer in HES and an EMR pathology record in the 
NOGCA, 9 (36%) of these patients had no record of 
malignancy, which suggests a cancer diagnosis was incor-
rectly recorded in HES. Finally, 13.1% of patients had no 
diagnosis codes related to oesophageal pathology at all 
recorded in HES.
This study suffers from various limitations. First, as 
this study used data collected for a national audit, it 
was not possible to access individual patient records to 
confirm the accuracy of submitted data, in terms of date 
of diagnosis and pathology results. Consequently it is 
possible if the date of diagnosis of HGD submitted to 
the audit was inaccurate, then the corresponding HES 
episode selected for analysis may not have been the right 
one. Second, as previously mentioned, we were unable 
to confirm whether the diagnosis of cancer recorded in 
HES at the time of diagnosis of HGD was in fact correct 
on original pathology reports.
Despite these limitations, the results highlight a 
significant problem for any national study looking 
at the management of HGD in England. The lack of 
a robust method for identifying these patients in a 
routine hospital database means it is not possible to 
estimate the incidence of the disease and the case 
ascertainment of national studies. This is of concern 
because early results from the NOGCA dataset showed 
that a third of patients with HGD were managed by 
surveillance alone,9 and it may be that this figure is 
even higher due to the effect of selection bias if the 
cases submitted to NOGCA are not representative of 
the national population.
The main reason for this situation concerns the lack 
of a specific code for Barrett’s oesophagus with HGD 
in the standard ICD-10 diagnosis codes. This limitation 
is not unique to ICD-10. For example, there is also no 
specific code for Barrett’s oesophagus with HGD within 
SNOMED. However, other countries have addressed 
this issue by producing a modified version of ICD-10, 
such as the ICD-10 Clinical Modification (CM) codes 
in the USA. The ICD-10-CM system of coding allows for 
up to seven characters to be recorded for each diag-
nostic field, incorporating greater detail about the 
diagnosis, for example, disease aetiology, anatomic site 
and laterality. In particular, the K22.7 code for Barrett’s 
oesophagus has been augmented to include codes for 
Barrett’s oesophagus with dysplasia (K22.719) and for 
Barrett’s oesophagus with high-grade and low-grade 
dysplasia (LGD) specifically (K22.711 and K22.710, 
respectively).10
In the UK, the introduction of ICD-11 is planned for 
2018. This will be an improvement because there are 
codes to distinguish between non-dysplastic Barrett’s 
oesophagus (EB90) and Barrett’s with dysplasia (EB91). 
The ability to further distinguish HGD from LGD 
within ICD-10-CM is important given the updated BSG 
guidelines recommend the treatment of confirmed 
LGD as well.4 With the rising incidence of oesopha-
geal adenocarcinoma, it is vital that there is a means to 
identify cases of oesophageal dysplasia in HES, so that 
the incidence can be monitored and national studies 
can be done to ensure it is being appropriately treated. 
We suspect this weakness is not limited to this clinical 
area, and consequently, we suggest that there would 
be considerable benefit to the UK if it adopted its own 
modification of the ICD-11 system for use in national 
databases such as HES.
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